Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3WZD

KDR in complex with ligand lenvatinib

3WZD の概要
エントリーDOI10.2210/pdb3wzd/pdb
関連するPDBエントリー3WZE
分子名称Vascular endothelial growth factor receptor 2, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, 2,3-DIHYDROXY-1,4-DITHIOBUTANE, ... (7 entities in total)
機能のキーワードkdr receptor kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
由来する生物種Homo sapiens (human)
細胞内の位置Cell junction . Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted . Isoform 3: Secreted: P35968
タンパク質・核酸の鎖数1
化学式量合計36821.08
構造登録者
Okamoto, K.,Ikemori_Kawada, M.,Inoue, A.,Matsui, J. (登録日: 2014-09-24, 公開日: 2015-05-27, 最終更新日: 2024-11-20)
主引用文献Okamoto, K.,Ikemori-Kawada, M.,Jestel, A.,von Konig, K.,Funahashi, Y.,Matsushima, T.,Tsuruoka, A.,Inoue, A.,Matsui, J.
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
ACS MED.CHEM.LETT., 6:89-94, 2015
Cited by
PubMed Abstract: Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction analysis of lenvatinib with VEGFR2 and X-ray analysis of the crystal structure of VEGFR2-lenvatinib complexes. Kinetic analysis revealed that lenvatinib had a rapid association rate constant and a relatively slow dissociation rate constant in complex with VEGFR2. Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.
PubMed: 25589937
DOI: 10.1021/ml500394m
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.57 Å)
構造検証レポート
Validation report summary of 3wzd
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon